Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 2/20 | 0.34 |
| ▸ | CASP7 | P55210 | 2/20 | 0.34 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.32 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.32 |
| ▸ | PPARG | P37231 | 4/20 | 0.31 |
| ▸ | PPARD | Q03181 | 4/20 | 0.31 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | DRD3 | P35462 | 1/20 | 0.31 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.31 |
| ▸ | CETP | P11597 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5498359 | 0.92 | CASP3 (0.34) | CASP3CASP7SIRT2SIRT1GRM2 | |
| SCHEMBL5506258 | 0.90 | SIRT2 (0.35) | CASP3CASP7SIRT2SIRT1PPARG | |
| SCHEMBL5503366 | 0.90 | ESR1 (0.42) | DRD3 | |
| SCHEMBL6104193 | 0.81 | KMT2A (0.37) | PPARGPPARDFFAR1DRD2DRD3 | |
| SCHEMBL6104358 | 0.75 | ESR1 (0.41) | — | |
| SCHEMBL5515348 | 0.72 | ESR1 (0.38) | SIRT2SIRT1CETP | |
| SCHEMBL6101506 | 0.71 | ESR1 (0.41) | DRD2DRD3 | |
| SCHEMBL6103061 | 0.70 | ESR1 (0.57) | — | |
| SCHEMBL5508174 | 0.69 | CA12 (0.33) | — | |
| SCHEMBL5498088 | 0.67 | LTA4H (0.44) | DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1778656-A1 | BENZOXAZEPINE DERIVATIVES AS SELECTIVE ESTROGEN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-02 | — | — | EP | disclosed |
| WO-2006023242-A1 | BENZOXAZEPINE DERIVATIVES AS SELECTIVE ESTROGEN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-03-02 | — | — | WO | disclosed |
| US-20060040917-A1 | Benzoxazepine derivatives as selective estrogen receptor modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060040917-A1 | Benzoxazepine derivatives as selective estrogen receptor modulators | GPER1, ESR2, ESR1 | CASP3 3856/4885CASP7 4451/4885SIRT2 1216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.